Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.

MLA

Paller, Amy S., et al. “Efficacy and Safety of Dupilumab with Concomitant Topical Corticosteroids in Children 6 to 11 Years Old with Severe Atopic Dermatitis: A Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trial.” Journal of the American Academy of Dermatology, vol. 83, no. 5, Nov. 2020, pp. 1282–93. EBSCOhost, https://doi.org/10.1016/j.jaad.2020.06.054.

APA

Paller, A. S., Siegfried, E. C., Thaçi, D., Wollenberg, A., Cork, M. J., Arkwright, P. D., Gooderham, M., Beck, L. A., Boguniewicz, M., Sher, L., Weisman, J., O’Malley, J. T., Patel, N., Hardin, M., Graham, N. M. H., Ruddy, M., Sun, X., Davis, J. D., Kamal, M. A., … Shumel, B. (2020). Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology, 83(5), 1282–1293. https://doi.org/10.1016/j.jaad.2020.06.054

Chicago

Paller, Amy S, Elaine C Siegfried, Diamant Thaçi, Andreas Wollenberg, Michael J Cork, Peter D Arkwright, Melinda Gooderham, et al. 2020. “Efficacy and Safety of Dupilumab with Concomitant Topical Corticosteroids in Children 6 to 11 Years Old with Severe Atopic Dermatitis: A Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trial.” Journal of the American Academy of Dermatology 83 (5): 1282–93. doi:10.1016/j.jaad.2020.06.054.